TABLE 1.
Selected model inputs.
| Variables | Value | Range | Distribution | Reference |
|---|---|---|---|---|
| Clinical event probabilities | ||||
| HFrEF population | ||||
| Cardiovascular death | ||||
| Control group | 0.0212 | 0.01908–0.02332 | Beta | Packer et al. (2020) |
| Empagliflozin group | 0.01956 | 0.01760–0.02152 | Beta | Packer et al. (2020) |
| Hospitalization for heart faliure | ||||
| Control group | 0.03719 | 0.03347–0.04091 | Beta | Packer et al. (2020) |
| Empagliflozin group | 0.02619 | 0.02357–0.02881 | Beta | Packer et al. (2020) |
| Readmission for heat faliure | 0.331 | 0.2979–0.3641 | Beta | Desai et al. (2016) |
| HFpEF population | ||||
| Cardiovascular death | ||||
| Control group | 0.00975 | 0.00877–0.01072 | Beta | Anker et al. (2021) |
| Empagliflozin group | 0.00864 | 0.00778–0.00951 | Beta | Anker et al. (2021) |
| Hospitalization for heart faliure | ||||
| Control group | 0.02003 | 0.01803–0.02204 | Beta | Packer et al. (2021) |
| Empagliflozin group | 0.01466 | 0.01319–0.01613 | Beta | Packer et al. (2021) |
| Readmission for heat faliure | 0.417 | 0.3753–0.4587 | Beta | Carson et al. (2015) |
| Probability of non-CV mortality by age | ||||
| 65–69 years | 0.2430% | (National Center for Chronic and Noncommunicable Disease Control and Prevention, 2019) | ||
| 70–74 years | 0.3042% | (National Center for Chronic and Noncommunicable Disease Control and Prevention, 2019) | ||
| 75–79 years | 0.4185% | (National Center for Chronic and Noncommunicable Disease Control and Prevention, 2019) | ||
| Utility (HFrEF) | ||||
| NYHA I | 1.000 | 0.950–1.000 | Beta | Di Tanna et al. (2021) |
| NYHA II | 0.860 | 0.817–0.903 | Beta | Di Tanna et al. (2021) |
| NYHA III | 0.600 | 0.570–0.630 | Beta | Di Tanna et al. (2021) |
| NYHA IV | 0.280 | 0.266–0.294 | Beta | Di Tanna et al. (2021) |
| Utility (HFpEF) | ||||
| NYHA I | 1.000 | 0.950–1.000 | Beta | Di Tanna et al. (2021) |
| NYHA II | 0.830 | 0.789–0.872 | Beta | Di Tanna et al. (2021) |
| NYHA III | 0.550 | 0.523–0.578 | Beta | Di Tanna et al. (2021) |
| NYHA IV | 0.270 | 0.257–0.284 | Beta | Di Tanna et al. (2021) |
| Hospitalization and readmission | −0.1 | −0.13–-0.08 | Beta | King et al. (2016) |
| Cost | ||||
| Standard therapy | $131.96 | $131.96–310.83 | Gammma | Huang et al. (2017) |
| Empagliflozin | $59.63 | $47.70–71.55 | Gammma | Local data |
| Hospitalization and readmission | $1,783.39 | $1,029.73–3,336.39 | Gammma | Ma, (2021) |
| Discounted rate | 5% | 0%–8% | Liu (2020) | |